MDA Awards $500,000 Grant to Accelerate ALS Research Through the HEALEY ALS Platform Trial at Massachusetts General Hospital
September 19, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce a new clinical research grant of $500,000 over three years, awarded to Sabrina Paganoni,...
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 16, 2024 08:00 ET
|
Actuate Therapeutics
Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT)Initial Data Demonstrates...
Rita and Alex Hillman Foundation Announces $500,000 in Funding for Nine Projects to Improve Serious Illness and End of Life Care
September 10, 2024 11:01 ET
|
Rita & Alex Hillman Foundation
RITA AND ALEX HILLMAN FOUNDATION ANNOUNCES $500,000 IN GRANTS TO IMPROVE SERIOUS ILLNESS AND END OF LIFE CARE, WITH THE ARTHUR VINING DAVIS FOUNDATIONS.
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
September 10, 2024 07:30 ET
|
Reunion Neuroscience Inc.
MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health...
ACGME Announces Next President and Chief Executive Officer
August 15, 2024 11:25 ET
|
Accreditation Council for Graduate Medical Education
Chicago, IL, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Accreditation Council for Graduate Medical Education (ACGME) is pleased to announce the appointment of Debra Weinstein, MD as its new President and...
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 01, 2024 06:45 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Global Experts to Convene for the Emerging Technologies for Diagnostics & Liquid Biopsies Conference 2024 in New Orleans (September 26-27th 2024)
June 26, 2024 04:01 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024" conference has been added to ResearchAndMarkets.com's offering. The...
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
June 17, 2024 07:00 ET
|
Helius Medical Technologies, Inc.
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S....
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...